These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10960371)

  • 1. A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary bypass: a pilot investigation.
    Hansen R; Koster A; Kukucka M; Mertzlufft F; Kuppe H
    Anesth Analg; 2000 Sep; 91(3):533-8. PubMed ID: 10960371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.
    Koster A; Despotis G; Gruendel M; Fischer T; Praus M; Kuppe H; Levy JH
    Anesth Analg; 2002 Jul; 95(1):26-30, table of contents. PubMed ID: 12088937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability of the heparin management test for monitoring high levels of unfractionated heparin: in vitro findings in volunteers versus in vivo findings during cardiopulmonary bypass.
    Mertzlufft F; Koster A; Hansen R; Risch A; Kuppe H; Kübel B; Crystal GJ
    Anesthesiology; 2000 Jun; 92(6):1594-602. PubMed ID: 10839908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma.
    Brooks MB
    Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
    Hellstern P; Bach J; Simon M; Saggau W
    J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.
    Despotis GJ; Summerfield AL; Joist JH; Goodnough LT; Santoro SA; Spitznagel E; Cox JL; Lappas DG
    J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1076-82. PubMed ID: 7983877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
    Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
    J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device.
    Koster A; Loebe M; Hansen R; Bauer M; Mertzlufft F; Kuppe H; Hetzer R
    J Thorac Cardiovasc Surg; 2000 Jun; 119(6):1278-83. PubMed ID: 10838548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass.
    Gruenwald C; de Souza V; Chan AK; Andrew M
    Perfusion; 2000 Jun; 15(3):203-9. PubMed ID: 10866421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery.
    Niles SD; Sutton RG; Ploessl J; Pennell B
    J Extra Corpor Technol; 1995 Dec; 27(4):197-200. PubMed ID: 10172651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated Clotting Time (ACT) for Monitoring of Low-Dose Heparin: Performance Characteristics in Healthy Adults and Critically Ill Patients.
    Wehner JE; Boehne M; David S; Brand K; Tiede A; Bikker R
    Clin Appl Thromb Hemost; 2020; 26():1076029620975494. PubMed ID: 33350327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a new protamine titration method to assay heparin in whole blood and plasma.
    Schlueter AJ; Pennell BJ; Olson JD
    Am J Clin Pathol; 1997 May; 107(5):511-20. PubMed ID: 9128262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.
    Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ
    Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
    Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real time measurement of heparin concentration during cardiopulmonary bypass.
    Hashimoto K; Sasaki T; Hachiya T; Takakura H; Onoguchi K; Nagahori R; Takeuchi S
    J Cardiovasc Surg (Torino); 1999 Oct; 40(5):645-51. PubMed ID: 10596996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.